Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

InterMune Achieves $10M Milestone from Roche

  • InterMune received $10-million upon completion of a large-scale synthesis of the active pharmaceutical ingredient in Roche’s hepatitis C virus (HCV) drug candidate. ITMN-191 is currently in a Phase Ia trial.

    This milestone is part of the companies' collaboration to develop and commercialize novel protease inhibitors for the treatment of HCV. 

    "InterMune has successfully executed key steps in the manufacture of a sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies," says Lawrence M. Blatt, Ph.D., CSO of InterMune.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »